Omega Therapeutics up on seeking FDA clearance for cancer therapy study

Omega Liquidating

15/06/2022 15:10

** Shares of drug developer Omega Therapeutics  OMGA.O  rise
2.6% to $2.76
    ** Co submits application to U.S. FDA seeking permission to
start early-stage clinical trial of lead cancer product
candidate, OTX-2002  urn:newsml:reuters.com:*:nPn8yRXHpa
    ** Co is developing OTX-2002 for the treatment of
hepatocellular carcinoma, the most common form of liver cancer
    ** Stock down ~77% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))